KR20060126659A - 키메라 항 ｃｄ44 항체 및 그 급성 골수성 백혈병 치료용용도 - Google Patents

키메라 항 ｃｄ44 항체 및 그 급성 골수성 백혈병 치료용용도 Download PDF

Info

Publication number
KR20060126659A
KR20060126659A KR1020067011975A KR20067011975A KR20060126659A KR 20060126659 A KR20060126659 A KR 20060126659A KR 1020067011975 A KR1020067011975 A KR 1020067011975A KR 20067011975 A KR20067011975 A KR 20067011975A KR 20060126659 A KR20060126659 A KR 20060126659A
Authority
KR
South Korea
Prior art keywords
antibody
ser
cells
val
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020067011975A
Other languages
English (en)
Korean (ko)
Inventor
플로렌스 스마드자
존 이. 딕
장 카두셰
Original Assignee
인스티튜트 내셔날 드 라 싼테 에 드 라 리셰르셰메디칼르(인썸)
유니버시티 헬스 네트워크
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 인스티튜트 내셔날 드 라 싼테 에 드 라 리셰르셰메디칼르(인썸), 유니버시티 헬스 네트워크 filed Critical 인스티튜트 내셔날 드 라 싼테 에 드 라 리셰르셰메디칼르(인썸)
Publication of KR20060126659A publication Critical patent/KR20060126659A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2884—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD44
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020067011975A 2003-11-19 2004-11-19 키메라 항 ｃｄ44 항체 및 그 급성 골수성 백혈병 치료용용도 Ceased KR20060126659A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03292873.1 2003-11-19
EP03292873A EP1532984A1 (en) 2003-11-19 2003-11-19 Use of anti CD44 antibodies for eradicating stem cells in acute myeloid leukemia

Publications (1)

Publication Number Publication Date
KR20060126659A true KR20060126659A (ko) 2006-12-08

Family

ID=34429570

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020067011975A Ceased KR20060126659A (ko) 2003-11-19 2004-11-19 키메라 항 ｃｄ44 항체 및 그 급성 골수성 백혈병 치료용용도

Country Status (10)

Country Link
US (4) US20050147606A1 (enExample)
EP (3) EP1532984A1 (enExample)
JP (1) JP2007513610A (enExample)
KR (1) KR20060126659A (enExample)
CN (1) CN1898268A (enExample)
AT (1) ATE480565T1 (enExample)
AU (1) AU2004290918B2 (enExample)
CA (2) CA2484459A1 (enExample)
DE (1) DE602004029078D1 (enExample)
WO (1) WO2005049082A2 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8071072B2 (en) * 1999-10-08 2011-12-06 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
EP2783700A1 (en) * 2006-09-07 2014-10-01 Stemline Therapeutics, Inc. Cancer stem cell-targeted cancer therapy
EP2526970A1 (en) * 2006-09-07 2012-11-28 Stemline Therapeutics, Inc. Monitoring cancer stem cells
UY30776A1 (es) * 2006-12-21 2008-07-03 Medarex Inc Anticuerpos cd44
EP2009028A1 (en) * 2007-06-27 2008-12-31 Monoclonal Antibodies Therapeutics Combination of a conventional anti-cancer treatment with anti-CD44 antibody administration for treating solid tumors
CN101368173B (zh) * 2008-04-09 2011-12-28 协和干细胞基因工程有限公司 抗人cd44的工程抗体、载体、试剂盒及其用途
AU2010221168A1 (en) * 2009-03-06 2011-10-06 Angstrom Pharmaceuticals, Inc. Compositions and methods for modulation of cell migration
PT2531527E (pt) * 2010-02-04 2014-05-16 Hoffmann La Roche Anticorpo monoclonal contra cd44 para ser utilizado no tratamento de carcinoma de células escamosas da cabeça e do pescoço
JP2014502258A (ja) * 2010-10-22 2014-01-30 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド 免疫反応を抑制するためにプログラムされた制御性ｔ細胞の発見
SG11201401405PA (en) * 2011-10-26 2014-05-29 Univ California Cd44 monoclonal antibody for the treatment of b-cell chronic lymphocytic leukemia and other hematological malignancies
WO2014201417A1 (en) * 2013-06-14 2014-12-18 The University Of Kansas Methods and compositions of modulating tumor initiating cells and the use thereof
NL2011904C2 (en) * 2013-12-06 2015-06-09 Stichting Vu Vumc Leukemic stem cell markers.
WO2019084240A1 (en) * 2017-10-25 2019-05-02 Actinium Pharmaceuticals, Inc. METHODS OF TREATING CANCER USING RADIO-labeled CD45 ANTI-CD45 IMMUNOGLOBULIN AND ADOPTIVE CELLULAR THERAPIES
EP4103610A1 (en) * 2020-02-13 2022-12-21 UCB Biopharma SRL Anti cd44-ctla4 bispecific antibodies
CN113552363B (zh) * 2020-04-03 2024-03-08 中国科学院广州生物医药与健康研究院 Cd44作为造血干/祖细胞的标志物及其应用
EP4153192B8 (en) 2020-05-19 2024-09-04 Institut Curie Antagonist of cd44/hyaluronic acid pathway for use in a method for the treatment of cytokine release syndrome
CA3220458A1 (en) 2021-05-18 2022-11-24 Janssen Biotech, Inc. Compositions comprising a t cell redirection therapeutic and an anti-cd44 therapeutic
CN114213538B (zh) * 2021-12-24 2022-07-08 北京市神经外科研究所 Cd44抗体、嵌合抗原受体及其应用
CN114316049B (zh) * 2021-12-24 2022-08-09 北京市神经外科研究所 Cd44抗体、嵌合抗原受体及其应用
WO2024040195A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
WO2024170543A1 (en) 2023-02-14 2024-08-22 Institut National de la Santé et de la Recherche Médicale Anti-cd44 antibodies and uses thereof
AU2024279278A1 (en) 2023-05-31 2025-12-18 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
IL327045A (en) 2023-10-05 2026-05-01 Capstan Therapeutics Inc Structure-restricted ionizable cationic lipids and lipid nanoparticles
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
US20250302763A1 (en) 2024-02-22 2025-10-02 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994009811A1 (en) * 1992-10-30 1994-05-11 Duke University An adhesion molecule
FR2715664B1 (fr) 1994-01-31 1996-04-12 Proteine Performance Sa Baculovirus recombinant et son utilisation pour la production d'anticorps monoclonaux.
US6492332B1 (en) * 1995-12-12 2002-12-10 Omeros Corporation Irrigation solution and methods for inhibition of tumor cell adhesion, pain and inflammation
EP0826696B1 (de) * 1996-09-03 2002-05-29 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Verwendung bi-und trispezifischer Antikörper zur Induktion einer Tumorimmunität
JPH10301492A (ja) * 1997-04-23 1998-11-13 Sony Corp 暗号化装置および方法、復号装置および方法、並びに情報処理装置および方法
KR100653803B1 (ko) * 2000-01-21 2006-12-05 소니 가부시끼 가이샤 데이터 처리 시스템 및 데이터 처리 시스템에서의 데이터 처리 방법
TW538636B (en) * 2000-09-01 2003-06-21 Matsushita Electric Industrial Co Ltd Reproduction equipment, reproduction equipment specifying equipment, reproduction equipment specifying system and methods and recording media for said equipment and system
US6972324B2 (en) * 2001-05-18 2005-12-06 Boehringer Ingelheim Pharmaceuticals, Inc. Antibodies specific for CD44v6
DK1401869T3 (da) * 2001-06-01 2008-04-28 Biogen Idec Inc Molekyler og fremgangsmåder til inhibering af udskillkelse af kim 1

Also Published As

Publication number Publication date
EP1692183B1 (en) 2010-09-08
CN1898268A (zh) 2007-01-17
EP2275444A1 (en) 2011-01-19
WO2005049082A3 (en) 2005-11-10
EP1692183A2 (en) 2006-08-23
DE602004029078D1 (de) 2010-10-21
CA2546566A1 (en) 2005-06-02
AU2004290918B2 (en) 2012-03-08
US20050147606A1 (en) 2005-07-07
WO2005049082A2 (en) 2005-06-02
CA2484459A1 (en) 2005-05-19
US20070237761A1 (en) 2007-10-11
US20070184051A1 (en) 2007-08-09
EP1532984A1 (en) 2005-05-25
ATE480565T1 (de) 2010-09-15
US20100040540A1 (en) 2010-02-18
AU2004290918A1 (en) 2005-06-02
JP2007513610A (ja) 2007-05-31

Similar Documents

Publication Publication Date Title
KR102809618B1 (ko) Tslp에 결합하는 항체 및 이의 용도
KR102773187B1 (ko) Cldn18.2 항체 및 이의 용도
CN101849006B (zh) 改良的抗体分子
KR102553870B1 (ko) 인간 카나비노이드 1(cb1) 수용체 결합 항체
CN115151570B (zh) 抗人cd19抗体
KR102815628B1 (ko) 인간화 항-il17a 항체 및 이의 용도
CN101205255A (zh) 抗cd20四价抗体、其制备方法和应用
KR20110119720A (ko) 항-ｃｄ 160 모노클로널 항체 및 그 용도
KR20240019218A (ko) T 세포 관여자 분자 및 이의 용도
CN106573977A (zh) 针对ceacam1的人源化抗体
KR102478986B1 (ko) 암 치료용 항-ck8 항체
KR102802041B1 (ko) 항-케모카인 유사 수용체 1 항체 및 이의 치료적 용도
CN110945022A (zh) 作为疫苗及新疟疾疫苗和抗体结合靶标的疟原虫子孢子npdp肽
KR20230152062A (ko) 항tslp 항체를 포함하는 의약 조성물
KR20210044262A (ko) Cd200r 효능제 항체 및 그의 용도
AU2020316498A1 (en) Humanized anti-VEGF monoclonal antibody
CN104558194B (zh) 一类抗CD20-Flex双功能融合蛋白、其制备方法及用途
CN102030827A (zh) 一种高亲和力的抗her2单克隆抗体
KR20230165285A (ko) Gdf15 신호전달의 치료적 억제제
CN112175087A (zh) 一种抗CD4和TGFβ的双特异性抗体、其药物组合及其用途
CN104610453A (zh) 一类抗her2双靶向抗体、其制备方法及用途
CN108948195B (zh) 一种抗egfr/pd-l1双靶向抗体、其制备方法及用途
CN104447993A (zh) 一种高活性全人源抗her2单克隆抗体、其制备方法及用途
KR20220151684A (ko) 암의 치료 및/또는 예방을 위한 의약품
AU2022290831B2 (en) Humanized anti-clec-1a antibodies and antigen-binding fragments thereof and mimetics thereof

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20060616

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20091119

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20110720

Patent event code: PE09021S01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20130214

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20130419

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20130214

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

Patent event date: 20110720

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I